News & Events

A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer

A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer

Jacobio's KRAS G12C and SHP2 Combination Therapy Published in The Lancet Respiratory Medicine

Jacobio's KRAS G12C and SHP2 Combination Therapy Published in The Lancet Respiratory Medicine

Clinical Trial: KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Clinical Trial: KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

U.S. Clinical Trial: Merck Sharp & Dohme LLC Listed a New Clinical Trial to Study Pembrolizumab Plus MK-1084 in Participants with Non-Small Cell Lung Cancer...

U.S. Clinical Trial: Merck Sharp & Dohme LLC Listed a New Clinical Trial to Study Pembrolizumab Plus MK-1084 in Participants with Non-Small Cell Lung Cancer...

KRAS mutations and lung cancer: Treatment and outlook

KRAS mutations and lung cancer: Treatment and outlook

Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer

Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer

Clinical Trial: Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

Clinical Trial: Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC